Shire plc - FORM 8-K - EX-99.1 - EXHIBIT 99.1

Attached files

file	filename
8-K - FORM 8-K - Shire plc	dp67142_8k.htm

Exhibit 99.1

Press Release

www.shire.com

Holding(s) in Company

July 11, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ⁱⁱ			Shire plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Decrease in voting rights ownership due to company increase in shares outstanding			X
3. Full name of person(s) subject to the notification obligation:ⁱⁱⁱ		Harbor International Fund (a series of Harbor Funds, a Delaware Statutory Trust)
4. Full name of shareholder(s) (if different from 3.):^iv
5. Date of the transaction and date on which the threshold is crossed or reached: ^v		Trade Date: June 30, 2016 Settlement Date: July 5, 2016
6. Date on which issuer notified:		July 8, 2016
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}		3% of issuer’s voting rights

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Common

SEDOL: B2QKY05

19,156,536

N/A

2.13%

N/A

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

N/A

Nominal

Delta

N/A

Total (A+B+C)

Number of voting rights

Percentage of voting rights

19,156,536

2.13%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
N/A

Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A

13. Additional information:	Completed in Chicago, Illinois, USA on July 8, 2016
14. Contact name:	Jodie L. Crotteau Assistant Secretary
15. Contact telephone number:	312-443-4428

For further information please contact:

Investor Relations

Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

NOTES TO EDITORS

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

Attached files

Stock widget

Investing forum

Shire plc Reports